Functional evaluation of immune cell therapy products is a critical element of quality control, confirming that CAR-T, NK, CIK, TIL and other adoptive cell therapies meet identity, purity, viability, and potency requirements before clinical use. This technical article outlines the sample types, testing items, analytical methods, and applications involved in comprehensive immune cell functional assessment, supporting compliance with international standards such as ISO/IEC 17025 and compendial requirements.
Technical Overview
Immune cell therapy, also known as adoptive cellular immunotherapy, involves the ex vivo activation, expansion, or genetic modification of immune cells—such as T cells, natural killer (NK) cells, cytokine-induced killer (CIK) cells, tumor-infiltrating lymphocytes (TILs), and dendritic cells (DCs)—for administration to patients, primarily in oncology and increasingly in autoimmune and infectious disease indications. Because these products are living biological medicines, quality cannot be assured by end-product testing alone; functional evaluation must be integrated throughout the manufacturing chain, from starting material characterization to final batch release.
Functional evaluation encompasses a multi-parametric testing strategy designed to demonstrate product identity, purity, viability, potency, and safety. Potency, defined as the specific ability of a product to achieve a defined biological effect, is widely recognized as the most challenging quality attribute, since no single assay fully predicts clinical efficacy. A battery of complementary assays covering cytotoxic activity, cytokine secretion, proliferation capacity, phenotypic composition, and target engagement is therefore employed.
Testing should be performed under appropriate quality systems. Accredited third-party laboratories operating in accordance with ISO/IEC 17025 general requirements for the competence of testing laboratories, together with relevant compendial and national standards (e.g., ISO 15189, applicable USP cell and gene therapy chapters, and relevant GB/T standards), provide traceable and defensible data suitable for regulatory submissions and batch release decisions.
Testing Samples
Functional evaluation can be applied to a wide range of immune cell therapy materials at different stages of development and manufacturing.
Chimeric Antigen Receptor T-Cell (CAR-T) Products
Final drug product, in-process intermediates, and post-thaw samples of autologous or allogeneic CAR-T cells targeting antigens such as CD19, CD22, and BCMA, as well as solid tumor-associated antigens. Key attributes include CAR expression (transduction efficiency), T-cell subset composition, exhaustion status, and antigen-specific cytotoxicity.
NK and CIK Cell Products
Ex vivo expanded NK cells derived from peripheral blood, umbilical cord blood, or induced pluripotent stem cell lines, together with CIK cell products. Evaluation focuses on activating receptor expression, degranulation capacity (CD107a), natural cytotoxicity, and antibody-dependent cellular cytotoxicity (ADCC).
Tumor-Infiltrating Lymphocyte (TIL) Products
Lymphocytes harvested from tumor tissue and expanded through rapid expansion protocols. Functional testing verifies reactivity against autologous tumor cells or HLA-matched targets, viability after expansion, and effector-memory phenotype distribution.
Dendritic Cell Vaccines and Other Engineered Immune Cells
Dendritic cell vaccines loaded with tumor antigens, gamma-delta T cells, macrophage-based products, and gene-edited immune cells. Assessment includes maturation markers (CD80, CD83, CD86), antigen presentation capacity, and T-cell stimulation activity.
Starting Materials and Cryopreserved Final Products
Leukapheresis material, peripheral blood mononuclear cells (PBMCs), and cryopreserved final products evaluated post-thaw to confirm functional recovery, stability profile, and suitability for infusion.
Testing Items
A comprehensive functional evaluation program typically addresses the following quality attributes:
- Cell identity: surface marker characterization (e.g., CD3, CD4, CD8, CD56, CD14) and CAR or transgene expression rate.
- Viability: membrane integrity, apoptotic and necrotic cell fractions, and post-thaw recovery.
- Purity and impurities: proportion of target effector cells, residual non-target populations, residual activation beads or feeder cells, and process-related contaminants.
- Cytotoxic potency: target cell killing against tumor cell lines, primary tumor cells, or antigen-specific targets across multiple effector-to-target (E:T) ratios.
- Cytokine secretion profile: IFN-gamma, TNF-alpha, IL-2, IL-6, GM-CSF, and related analytes following antigen-specific or non-specific stimulation.
- Proliferation and expansion capacity: cumulative fold expansion, Ki-67 expression, dye-dilution proliferation assays, and response to re-stimulation.
- Phenotype and differentiation status: naive, central memory, effector memory, and terminal effector subsets; activation markers (CD25, CD69, HLA-DR); exhaustion markers (PD-1, TIM-3, LAG-3, TIGIT).
- Degranulation and cytotoxic machinery: CD107a mobilization, perforin and granzyme B content.
- Safety-related testing: sterility, mycoplasma, bacterial endotoxin, vector copy number, and replication-competent virus screening where applicable.
- Cell count, total dose, and viability at the point of release.
Testing Methods
Multiparameter Flow Cytometry
The cornerstone technique for identity, purity, phenotype, viability (7-AAD, DAPI, Annexin V), CAR expression, and intracellular cytokine staining. Multi-color panels enable simultaneous assessment of subset composition, memory differentiation, activation, and exhaustion within a single acquisition, aligned with recognized flow cytometry guidance.
Cytotoxicity Assays
Target cell killing is quantified using LDH release assays, calcein-AM or chromium-51 release assays, bioluminescence-based killing assays with luciferase-expressing target cells, flow cytometric measurement of viable target cell loss, and label-free real-time cell analysis platforms that generate kinetic killing profiles across a range of E:T ratios.
Cytokine and Soluble Factor Analysis
ELISA, ELISpot, FluoroSpot, and multiplex bead-based assays quantify secreted cytokines and chemokines. ELISpot additionally provides single-cell functional resolution of antigen-specific IFN-gamma responses.
Proliferation and Metabolic Fitness Assays
CFSE or CellTrace dye dilution, Ki-67 intracellular staining, ATP-based metabolic activity assays, and mitochondrial fitness analyses support evaluation of expansion potential and durable functional capacity.
Molecular and Microbiological Methods
Quantitative PCR and digital droplet PCR for vector copy number and transgene quantification, rapid microbiological methods for sterility and mycoplasma detection, and LAL-based endotoxin testing complete the safety panel. All cell handling is performed under biosafety conditions appropriate to the product type.
Applications
Functional evaluation data underpin the entire life cycle of immune cell therapy development and commercialization:
- Lot release testing: objective evidence that each clinical batch meets predefined acceptance criteria for identity, purity, viability, and potency prior to infusion.
- Process development and optimization: comparative evaluation of culture conditions, activation strategies, and gene transfer methods based on functional readouts.
- Comparability and change control: demonstration of product equivalence following manufacturing, formulation, or site changes.
- Stability and shelf-life studies: assessment of functional retention during cryopreservation and post-thaw holding periods.
- Potency assay development and validation: establishment of phase-appropriate potency matrices aligned with regulatory expectations.
- Preclinical and translational research support: characterization of candidate products before first-in-human studies.
FAQ
Why is potency testing so important for immune cell therapy products?
Regulatory authorities worldwide require a validated potency assay or potency matrix to link product quality to expected clinical activity. Because immune cell products are complex living medicines, a combination of complementary functional assays provides the strongest evidence that each batch will perform as intended in the patient.
Which standards govern functional evaluation of immune cell products?
Testing is typically performed under ISO/IEC 17025 laboratory quality systems, with reference to ISO 15189 for medical laboratories, applicable compendial cell and gene therapy chapters, and relevant national standards such as GB/T specifications. These frameworks ensure method validation, traceability, and data integrity.
What sample types and quantities are required?
Both fresh and cryopreserved samples can be evaluated. Typical submissions range from one to tens of millions of cells, depending on the assay panel. Cryopreserved samples should be shipped on dry ice with certified cold-chain documentation, while fresh samples require controlled-temperature transport with defined time windows.
How long does functional evaluation take?
Flow cytometry and viability testing can generally be completed within a few working days. Cytotoxicity assays require target cell co-culture of approximately 4 to 24 hours plus analysis time, and a full multi-assay characterization package is typically reported within one to two weeks of sample receipt.
Can a single assay fully predict clinical efficacy?
No single assay fully predicts clinical outcome. A potency matrix combining cytotoxicity, cytokine release, phenotype, and proliferation data provides a more reliable, multi-dimensional picture of product function and is the recommended approach for release and stability testing.
Are data from external laboratories acceptable for regulatory submissions?
Yes. Data generated by accredited third-party laboratories using validated methods, documented quality systems, and full data traceability are widely accepted in support of investigational and marketing applications, provided the laboratory meets the applicable competence and biosafety requirements.